Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer

斯晓燕; 张力

您当前的位置：

首页 >

文章列表页 >

Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer

更新时间：2026-01-09

- Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer
- Journal of Army Medical University Vol. 34, Issue 20, Pages: 2063-2066(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R730.5;R734.2;R979.1
- Published：2012
- 稿件说明：
移动端阅览
斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].陆军军医大学学报(原第三军医大学学报),2012,34(20):2063-2066.

　Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(20):2063-2066.
斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].陆军军医大学学报(原第三军医大学学报),2012,34(20):2063-2066. DOI：

　Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(20):2063-2066. DOI：

摘要

目的研究西妥昔单抗联合化疗一线治疗非小细胞肺癌（non-small cell lung cancer

NSCLC）的疗效。方法回顾性分析北京协和医院呼吸内科2008年11月至2012年4月使用西妥昔单抗联合化疗的20例非小细胞肺癌患者的临床资料，进行疗效和安全性评估。所有患者签署了知情同意书，并同意提供临床资料。结果截至分析之日尚有8例患者仍存活，最长1例用药后存活了39.8个月。客观反应率（ORR）、疾病控制率（DCR）、无进展生存（PFS）和总生存（OS）时间分别为50.0%、70.0%、8.6个月和10.9个月。常见的毒副反应包括皮肤毒性（15例，75.0%）、谷丙转氨酶升高（3例，15.0%）、血液系统毒性（2例，10.0%）、过敏（1例，5.0%）和发热（1例，5.0%）。结论 NSCLC患者使用西妥昔单抗联合化疗作为一线治疗疗效好，严重的毒副反应发生率低且可以控制，但尚需要寻找合适的预测性标记物来筛选治疗的受益人群。

Abstract

Objective To evaluate the safety and efficacy of cetuximab combined with chemotherapy as first line therapy in patients with non-small cell lung cancer (NSCLC). Methods A retrospective analysis of clinical data was conducted in 20 patients who were given cetuximab combined with chemotherapy as first line therapy in our department between November 2008 and April 2012. All patients signed the informed consent

and consented to offer clinical information. Results Eight patients were alive up to the time of our analysis

and the longest survival was 39.8 months. The objective response rate (ORR)

disease control rate (DCR)

median progression free survival (PFS)

and estimated least median overall survival (OS) were 50.0%

70.0%

8.6 months and 10.9 months

respectively. The common adverse events included skin toxicity (15

75.0%)

alanine aminotransferase elevation (3

15.0%)

hematological toxicity (2

10.0%)

allergy (1

5.0%) and fever (1

5.0%). Conclusion Cetuximab combined with chemotherapy as first line therapy for patients with NSCLC has promising ORR

DCR

and PFS. Serious adverse events are of low incidence and quite controllable. We should search predictive factors for selecting appropriate patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Integrative model combining deep learning, clinical and radiomic features enhances EGFR mutation prediction in non-small cell lung cancer

Preparation of doxorubicin-loaded polyphyllin H liposomes and synergistic anti-tumor activity against non-small cell lung cancer in vitro

Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer

Effect of chronic obstructive pulmonary disease on immunotherapy in patients with advanced non-small cell lung cancer

Related Author

YANG Taotao

CHEN Wei

CHEN Cancan

YAN Wanying

WANG Dawei

XIONG Kunlin

SUN Zhiyuan

WANG Xianqi

Related Institution

Department of Radiology，First Affiliated Hospital， Army Medical University （Third Military Medical University）

Infervision Medical Technology Co.， Ltd

Department of Radiology， Daping Hospital， Army Medical University

Department of Diagnostic Radiology， Eastern Theatre General Hospital

Department of Medical Service,No. Hospital of Joint Logistics Support Force

⁰